



P&T COMMITTEE MEETING

Agenda

October 6, 2015

1:00 p.m. – 5:00 p.m.

303 E. 17th Ave Conference room 11ABC
Denver, CO 80203

Committee Member Introductions

Unfinished Business and General Orders

- Approval of minutes for the July 7, 2015 meeting
- Update on Oral anticoagulants
- Update on Bisphosphonates
- Update on Oral biguanides
- Update on Hypoglycemic combinations
- Update on Meglitinides
- Update on DPP4, SGLT2, GLP1, Amylin
- Update on Thiazolidinediones
- Update on Erythropoiesis stimulating agents
- Update on Overactive bladder agents
- Update on Hepatitis C agents
- Update on Stimulants and ADHD

New Business

1. P&T Committee member term expirations and open positions
2. Updates from the Prior Authorization Call Center

3. **Drug Classes Up for Review:**

Each review will contain public testimony, class updates and market share, and Committee discussion:

- Review of Antiemetics
- Review of New Generation Antidepressants
- Review of Anti-herpetics
- Review of Anti-platelets
- Review of Fluoroquinolones
- Review of Pancreatic Enzymes
- Review of Proton Pump Inhibitors
- Review of Pulmonary Arterial Hypertension agents
- Review of Targeted Immune Modulators (separated by indication)
- Review of Triptans

Each Review will contain:

- Drug class Overview and Agents up for review for each Drug Class

- Oral presentation by manufacturers, providers, and public following overview
- Committee Discussion and Recommendations for each Class

Upcoming Meeting Date: Tuesday, January 5, 2016; 1:00 p.m. – 5:00 p.m.

Interested parties who want to present at the meeting are encouraged to give advanced notice. Please contact Swaniece Grubb at 303-866-3614 or by email at Swaniece.grubb@state.co.us. Written public comments can be submitted to pdlproject@state.co.us and will be distributed to all present P&T Committee Members.